COSOPT is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta blockers (failed to achieve target IOP determined after multiple measurements over time). The IOP-lowering effect of COSOPT bid was slightly less than that seen with the concomitant administration of 0.5% timolol bid and 2.0% dorzolamide tid.

COSOPT is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease (see WARNINGS); (4) sinus bradycardia; (5) second- or third-degree atrioventricular block; (6) overt cardiac failure (see WARNINGS); (7) cardiogenic shock; or (8) hypersensitivity to any component of this product.

COSOPT contains dorzolamide, a sulfonamide, and timolol maleate, a beta-adrenergic blocking agent; and although administered topically, is absorbed systemically. Therefore, the same types of adverse reactions that are attributable to sulfonamides and/or systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma and, rarely, death in association with cardiac failure, have been reported following systemic or ophthalmic administration of timolol maleate.

The concomitant use of 2 topical beta-adrenergic blocking agents (eg, COSOPT and any topical beta-adrenergic blocking agent) is not recommended.

In clinical trials with COSOPT, the most frequently reported adverse events were taste perversion (bitter, sour, or unusual taste) or ocular burning and/or stinging in up to 30% of patients. Conjunctival hyperemia, blurred vision, superficial punctate keratitis, or eye itching were reported in 5% to 15% of patients. A comprehensive list of adverse events observed in clinical studies and postmarketing surveillance is included in the Prescribing Information.

This site is intended only for healthcare professionals of the United States, its territories, and Puerto Rico. COSOPT and OCUMETER are registered trademarks of Merck & Co., Inc.

For general information and other services for physicians